KCNJ11 and Hypoglycemia: Unfortunately, higher doses have not been evaluated in humans probably due to a human dose limitation of glibenclamide, as higher doses could lead to severe hypoglycemia owing to glibenclamide’s high affinity to the Kir6.2/SUR1 subtype of KATP channels present in the pancreas.